| Execution period | FY 2026-27 |
|---|
BSE filing, NSE: DCBBANK. Summary written from the filing by ALFA Finder's alert engine.
DCB Bank Ltd: key numbers
- Share price
- ₹192.10
- Market cap
- ₹6,189 Cr
- Revenue (annual)
- ₹7,404 Cr
- Net profit (annual)
- ₹731.6 Cr
- P/E (TTM)
- 7.4×Sector 19.1×
- Promoter holding
- 16.22%-0.01% QoQ
- FII holding
- 15.47%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from DCB Bank Ltd
All →DCB Bank Employee Stock Options
DCB Bank allotted 81,100 equity shares to employees under its ESOP plan on October 30, 2026. Paid-up capital rose to 322,270,512 shares.
DCB Bank Annual General Meeting
DCB Bank seeks shareholder approval via postal ballot to re-appoint Thiyagarajan Kumar as Independent Director for three years. E-voting runs from 27 October to 25 November 2026.
DCB Bank Earnings Call Transcript: Key Takeaways
DCB Bank delivers record quarterly net profit, hitting long-term ROE targets early despite NIM compression.
- Call
- Guides 20% growth
DCB Bank Management Change
DCB Bank's board re-appointed Mr. Praveen Kutty as Managing Director & CEO for three years from April 29, 2027 to April 28, 2030, subject to RBI terms and shareholder approval. No monetary value is involved in this senior management decision.
- Execution
- April 29, 2027 to April 28, 2030
DCB Bank Investor Presentation: Key Takeaways
Q2FY27 PAT INR 236 cr (+28.54% YoY); advances INR 64,127 cr (+21.05%); deposits INR 76,839 cr (+18.62%); GNPA 2.29%, NNPA 0.73%, ROE 14.60%. Secured retail and MSME growth focus.
DCB Bank Q2 FY27 Results: Net Profit ₹236.4 Cr, Up 28.5% YoY
DCB Bank Ltd reported revenue from operations of ₹2,050 Cr (+12.5% YoY) and net profit of ₹236.4 Cr (+28.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹236.4 Cr · +28.5% YoY
Other regulatory approval announcements
All →Vedavaag Systems Regulatory Approval
Vedavaag's WOS received IRDAI Certificate of Registration to act as Direct Life & General Insurance Broker. The group enters regulated insurance broking activity.
Hikal Regulatory Approval
Hikal's Bengaluru API facility received a Swissmedic GMP Certificate of Compliance. The certification supports wider access to European and other regulated markets.
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
RNFI Services Regulatory Approval
RNFI received RBI no-objection to acquire control of Smart Payment Solutions Private Limited. Remaining tranches may proceed, but no transaction value is disclosed.
Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.